GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomind Labs Inc (FRA:3XI) » Definitions » Earnings Yield (Joel Greenblatt) %

Biomind Labs (FRA:3XI) Earnings Yield (Joel Greenblatt) % : -1.07% (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Biomind Labs Earnings Yield (Joel Greenblatt) %?

Biomind Labs's Enterprise Value for the quarter that ended in Sep. 2024 was €25.60 Mil. Biomind Labs's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was €-0.30 Mil. Biomind Labs's Earnings Yield (Joel Greenblatt) for the quarter that ended in Sep. 2024 was -1.07%.

The historical rank and industry rank for Biomind Labs's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

FRA:3XI' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -115.8   Med: 0   Max: 92.59
Current: -1.35

During the past 3 years, the highest Earnings Yield (Joel Greenblatt) of Biomind Labs was 92.59%. The lowest was -115.80%. And the median was 0.00%.

FRA:3XI's Earnings Yield (Joel Greenblatt) % is ranked better than
75.39% of 1361 companies
in the Biotechnology industry
Industry Median: -13.81 vs FRA:3XI: -1.35

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biomind Labs's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2024 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Biomind Labs Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for Biomind Labs's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomind Labs Earnings Yield (Joel Greenblatt) % Chart

Biomind Labs Annual Data
Trend Dec21 Dec22 Dec23
Earnings Yield (Joel Greenblatt) %
-5.48 -6.03 -11.36

Biomind Labs Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Earnings Yield (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -8.85 -11.36 -2.88 -3.13 -1.07

Competitive Comparison of Biomind Labs's Earnings Yield (Joel Greenblatt) %

For the Biotechnology subindustry, Biomind Labs's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biomind Labs's Earnings Yield (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomind Labs's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Biomind Labs's Earnings Yield (Joel Greenblatt) % falls into.



Biomind Labs Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

Biomind Labss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2023 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-0.945/0.8055236
=-117.31 %

Biomind Labs's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.30 Mil.



Biomind Labs  (FRA:3XI) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


Biomind Labs Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Biomind Labs's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biomind Labs Business Description

Industry
Traded in Other Exchanges
Address
Camino Saravia s/n, Pando Science and Technology Park, Pando Canelones, Canelones, URY, CP 91.000
Biomind Labs Inc is a biotech Research and Development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and nanotech delivery systems for a variety of psychiatric and neurological conditions. Biomind is developing pharmaceutical sole and combined formulations of the main natural psychedelic molecules with the aim of identifying novel pharmaceutical compounds for treating a wide range of therapeutic indications.

Biomind Labs Headlines

No Headlines